AVN-322

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19N5O2S.ClH
Molecular Weight	393.891
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

Cl.CNC1=NN2C(N=CC3=C2CCN(C)C3)=C1S(=O)(=O)C4=CC=CC=C4

InChI

InChIKey=HLQZXWFRTGIZIJ-UHFFFAOYSA-N

InChI=1S/C17H19N5O2S.ClH/c1-18-16-15(25(23,24)13-6-4-3-5-7-13)17-19-10-12-11-21(2)9-8-14(12)22(17)20-16;/h3-7,10H,8-9,11H2,1-2H3,(H,18,20);1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H19N5O2S
Molecular Weight	357.43
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical
Record UNII	B7DM6S48B2
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

AVN-322

Code

English

PYRAZOLO(1,5-A)PYRIDO(3,4-E)PYRIMIDIN-2-AMINE, 6,7,8,9-TETRAHYDRO-N,7-DIMETHYL-3-(PHENYLSULFONYL)-, HYDROCHLORIDE (1:1)

Preferred Name

English

5-(BENZENESULFONYL)-N,11-DIMETHYL-2,3,7,11-TETRAAZATRICYCLO(7.4.0.0(2,6))TRIDECA-1(9),3,5,7-TETRAEN-4-AMINE HYDROCHLORIDE

Systematic Name

English

AVN322

Code

English

Showing 1 to 4 of 4 entries

Previous1Next

Show entries

Code System

Code

Type

Description

PUBCHEM

135905417

PRIMARY

CAS

1194574-68-9

PRIMARY

FDA UNII

B7DM6S48B2

PRIMARY

Showing 1 to 3 of 3 entries

Previous1Next

Show entries

Related Record

Type

Details


					B7DM6S48B2

AVN-322

ACTIVE MOIETY

Comments:

Originator: ChemDiv; Developer: AllaChem, Avineuro Pharmaceuticals; Class: Nootropic, Pyrimidine, Small molecule; Mechanism of Action: Serotonin 6 receptor antagonist; Orphan Drug Status: No; On Fast track: No; New Molecular Entity: Yes; Highest Development Phase: Phase I for Alzheimer's disease; Most Recent Events: 13 Nov 2013 Phase-I development is ongoing in USA, 13 Nov 2013 AVN 322 sublicensed to AllaChem before Nov 2013, 16 Jun 2009 Phase-I clinical trials in Alzheimer's disease in USA (unspecified route)


					B7DM6S48B2

AVN-322

ACTIVE MOIETY

Comments:

Company: Avineuro Pharmaceuticals Inc.; Description: Serotonin (5-HT6) receptor antagonist; Molecular Target: Serotonin (5-HT6) receptor; Mechanism of Action: Serotonin (5-HT6) receptor antagonist; Therapeutic Modality: Small molecule; Latest Stage of Development: Phase I; Standard Indication: Alzheimer's disease (AD); Indication Details: Treat Alzheimer's disease (AD); Partner: AllaChem LLC

Showing 1 to 2 of 2 entries

Previous1Next